Objectives: Daptomycin non-susceptibility in Staphylococcus aureus can emerge via the accumulation of single or multiple mutations, each resulting in a slight increase in the daptomycin MIC. The daptomycin-nonsusceptible phenotype may include other features such as daptomycin tolerance. This study identifies S. aureus genomic regions that frequently develop mutations following prolonged daptomycin exposure but have not been previously associated with daptomycin non-susceptibility.
Introduction
Daptomycin-non-susceptible (DNS) Staphylococcus aureus strains are observed clinically, particularly during prolonged antibiotic exposure, and are associated with treatment failure. Mutations in six genes, mprF, walKR, rpoBC and cls2, have individually been associated with daptomycin non-susceptibility, with mprF being the most prevalent. 1 Although some are sufficient for daptomycin non-susceptibility, none is uniquely necessary for the phenotype. Sequence polymorphisms in other loci are observed in DNS strains, but causality has not been established. These and other sequence polymorphisms may represent alternative pathways to the DNS phenotype and can identify core metabolic functions disturbed in response to daptomycin.
Compensatory responses to daptomycin may modulate growth rates, bypass daptomycin-disrupted pathways and/or promote antibiotic tolerance. Tolerance is distinct from resistance in that growth is restricted but viability is minimally affected. 2 Tolerance occurs among S. aureus isolates from persistent and recurrent bacteraemia, 3 a phenotype largely absent among isolates from rapidly resolving infection. 4 This reflects the discrepancy between a low rate of DNS S. aureus by MIC (2%) and the 15% rate of persistent bacteraemia with treatment. 5, 6 This study aimed to determine the effect of polymorphisms in nine additional genomic regions on daptomycin non-susceptibility, tolerance and organism survival upon daptomycin exposure. 
Materials and methods
MRSA strains J01 and J03 and in vitro-derived mutants have been described previously 7, 8 with sequence reads publically available in GenBank (PRJEB8645). J01 was subcultured daily in vitro for 28 days in parallel experiments containing escalating concentrations of daptomycin and static concentrations of either broth or adjunctive antibiotics. Serially passaged strains were renamed 'SP-' followed by identifiers for antibiotics included in serial passage and replicate number. Mueller-Hinton broth was supplemented to 50 mg/L calcium and 12.5 mg/L magnesium (MHB50). Brain heart infusion broth was solidified with 1.5% agar. MICs of antibiotics were determined in quadruplicate by microbroth dilution. 9 Candidates for allelic replacement were selected based on sequence variation occurring in at least 10% of in vitro-generated DNS genomes and in at least two passages containing different adjunctive antibiotics. Mutations in yycFG/walKR, rpoBC, mprF and cls2 were excluded as they constitute established mediators of the DNS phenotype and have been described elsewhere. 8 Targeted allelic replacement was accomplished utilizing the pIMAY-Z system (Table S1 , available as Supplementary data at JAC Online). 10 If multiple distinct variations were identified in the same locus, amplification from strains with WT growth rates was prioritized to mitigate the influence of growth rate changes on downstream analyses. All allelic replacement strains were confirmed free of second-site mutation by whole-genome sequencing. 8 Time-kill curve analyses were performed using static concentrations of 3.8 mg/L daptomycin. Cultures (10 6 cfu/mL) in MHB50 were shaken (180 rpm, 37 C) in triplicate and viable organisms enumerated by dilution plating. The area under the time-kill curve (AUC) was determined using the trapezoidal method. The lowest measurable quantity was 100 cfu/mL.
Tolerance-kill curve analyses were performed with supratherapeutic concentrations of antibiotic according to the method of Mechler et al.
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Overnight cultures (5%10 9 cfu/mL) were brought to 100 mg/L daptomycin (100 % MIC) and viable organism counts enumerated via dilution plating at predefined intervals. Minimum durations of exposure required to achieve 2 log and 4 log reductions in viability were calculated (MDK 99 2 MHB50 was supplemented to account for calcium internalization by the high bacterial inoculum (15%, data not shown). Samples were washed with normal saline prior to plating. AUC was determined using the trapezoidal method.
Continuous variables were summarized using the mean and SD, and compared using the two-tailed unpaired Student's t-test. P values of 0.05 were considered 'significant' following a post hoc Holm-Bonferroni adjustment for multiple comparisons.
Results
Nine loci were identified where mutation emerged independently in at least three DNS isolates (Table S2) . Technical challenges precluded further analysis of clpX mutations; therefore, the following data and discussion will exclude clpX and focus on the remaining eight loci. In this subset, 20 sequence polymorphisms were identified. In no region was mutation unique to a specific antibiotic combination exposure, indicating daptomycin selective pressure rather than any influence of other antibiotics. A comprehensive list of mutations is provided in Table S3 .
Introduction of mutations in snoF, sspA, hepT or amaP into J01 resulted in a modest increase in daptomycin MIC (from 0.25 to 0.5 mg/L). No changes to daptomycin MIC were observed when targeted mutations were introduced into the DNS J03 genomic background (daptomycin MIC " 2 mg/L) ( Table 1 ).
In kill curve analyses, mutation in either hepT or rsh resulted in significantly less extensive daptomycin killing compared with the J01 parent. In the DNS J03 genomic background, mutations in snoF, rimP, hepT, rsh or map1 resulted in significantly less extensive daptomycin killing (Table 1) . Only hepT affected growth, prolonging doubling time by 50%.
Mutation in any targeted locus, with the exception of hepT, resulted in significantly reduced daptomycin killing compared with J01 in the stationary phase (high inoculum) tolerance assay. Mutation in hmp1, rimP, rsh, map1 or amaP confers tolerance, and mutation in snoF or sspA confers heterotolerance (Figure 1) . Similar results were obtained for DNS J03 with minor distinctions of sspA conferring full tolerance and hepT conferring heterotolerance (data not shown).
Discussion
Daptomycin exposure has multiple physiological effects on staphylococci, resulting in bactericidal antimicrobial activity. Here we demonstrate that mutations in eight loci do not affect daptomycin MICs significantly but do contribute to survival in the presence of daptomycin. Since mutations identified in this work are not generally implicated in either cell envelope homeostasis or regulatory control (Table S4) , their role in enhancing cell survival during daptomycin exposure is unclear. Novel mediators of daptomycin tolerance JAC generated previously, resulting in resistance to host cationic peptide tPMP-1. 12 Daptomycin and host cationic peptides both act by disrupting membrane integrity, and cross-resistance has been reported. sspA SspA is a well-characterized extracellular protease and virulence factor, V8 protease.
14 The D234Y mutation identified in this work localizes to a C-terminal repeat region of unclear function.
rimP
RimP is a ribosome maturation factor involved in production of mature 30S ribosomal subunits. Several DNS strains in this study and others contain mutations in genes encoding additional ribosomal proteins including rplB, rplC, rplP, rplV and rpsU. However, no single subunit or ribosomal maturation factor appears uniquely responsible for mediating the DNS phenotype.
hepT The SAUSA300_RS07410 gene product resembles GerCC/HepT-like components of heterodimeric polyprenyl synthetases. Its local genomic context suggests involvement in menaquinone biosynthesis. rsh SAUSA300_RS08665 encodes Rsh, a bifunctional enzyme combining ppGpp synthesis and hydrolase activities. The modified guanosine nucleotide mediates the stringent response, a cellular program that modifies global transcription to rapidly adapt to cellular stresses. 15 Antibiotics can induce ppGpp synthesis and high ppGpp levels can reduce antibiotic activity, including daptomycin. 16 Mutations primarily map to the hydrolase domain and consequently are predicted to result in impaired ppGpp degradation. Mutations in rsh occur in small colony variant and persistent infections.
map1
SAUSA300_RS10105 encodes a membrane-associated protein (Map1) of unknown function. Allelic variants include frameshift and nonsense mutations, suggesting loss of function.
amaP AmaP is as a membrane anchor for alkaline shock protein (Asp23). Loss of either AmaP or Asp23 results in up-regulation of cell envelope stress response genes, including vraSR, a mediator of both daptomycin non-susceptibility and decreased resistance to oxacillin. 17 Overall, the contribution of these individual mutations to daptomycin MIC changes was only marginal despite the marked daptomycin MIC elevation in the previously described passaged strains. 1 Likewise, we observed a modest protective effect of several targeted mutations in the presence of therapeutically relevant daptomycin concentrations in the growth curve assay. Antimicrobial tolerance can contribute to clinical treatment failures. 2, 4 This trait may be shared by the entire population ('tolerant') or by only a small subpopulation ('heterotolerant'). 2, 4 In the current study, seven out of the eight mutations enhanced survival against concentrations of daptomycin at least 100-fold above the MIC. Strains containing mutations in hmp1, rimP, rsh, map1 or amaP were daptomycin tolerant, whereas two additional loci (snoF and sspA) confer heterotolerance.
rsh mutation and induction of the stringent response has already been implicated in antimicrobial tolerance from both clinical and lab-derived S. aureus. 18, 19 The relative ease with which rsh mutations were selected in the current study (24% of serial passage strains) and diverse SNP locations suggest a dysregulated stringent response results from direct mutation of RSH.
In summary, our study identifies the effect of eight novel mutations in S. aureus on evolution of daptomycin non-susceptibility. From these data, we posit that these mutations reduce daptomycin activity via adaptations to: (i) redirect around metabolic pathway disruption; (ii) alter growth rate to promote antimicrobial tolerance; (iii) modulate cell envelope characteristics without altering daptomycin susceptibility; or (iv) synergize with classical DNSconferring mutations. Although this work was performed in only one genetic background, these findings have important implications on the mechanisms of daptomycin tolerance, a continuing challenge in patients with invasive S. aureus infections.
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